Extensively drug-resistant tuberculosis: New strains, new challenges

Ritu Banerjee, Gisela F. Schecter, Jennifer Flood, Travis C. Porco

Research output: Contribution to journalReview articlepeer-review

32 Scopus citations


Extensively drug-resistant (XDR)-TB, defined as TB with resistance to at least isoniazid, rifampin, a fluoroquinolone and either amikacin, kanamycin or capreomycin, is a stark setback for global TB control. Overburdened public-health systems with inadequate resources for case detection and management and high HIV coinfection rates in many regions have contributed to the emergence of XDR-TB. Patients with XDR-TB have poor outcomes, prolonged infectious periods and limited treatment options. To prevent an epidemic of untreatable XDR-TB, improvements in XDR-TB surveillance, increased laboratory capacity for rapid detection of drug-resistant strains, better infection control and the development of new therapeutics are urgently needed.

Original languageEnglish (US)
Pages (from-to)713-724
Number of pages12
JournalExpert Review of Anti-Infective Therapy
Issue number5
StatePublished - Oct 2008


  • Drug-susceptibility testing
  • Extensively drug-resistant tuberculosis
  • Multidrug-resistant tuberculosis
  • Second-line drug
  • Tuberculosis

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)
  • Virology
  • Infectious Diseases


Dive into the research topics of 'Extensively drug-resistant tuberculosis: New strains, new challenges'. Together they form a unique fingerprint.

Cite this